Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

BACKGROUND: PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each developed with a different ICI. We set to test if next generation...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Conroy, Jeffrey M., Pabla, Sarabjot, Nesline, Mary K., Glenn, Sean T., Papanicolau-Sengos, Antonios, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Wang, Yirong, Lenzo, Felicia L., Bshara, Wiam, Khalil, Maya, Dy, Grace K., Madden, Katherine G., Shirai, Keisuke, Dragnev, Konstantin, Tafe, Laura J., Zhu, Jason, Labriola, Matthew, Marin, Daniele, McCall, Shannon J., Clarke, Jeffrey, George, Daniel J., Zhang, Tian, Zibelman, Matthew, Ghatalia, Pooja, Araujo-Fernandez, Isabel, de la Cruz-Merino, Luis, Singavi, Arun, George, Ben, MacKinnon, Alexander C., Thompson, Jonathan, Singh, Rajbir, Jacob, Robin, Kasuganti, Deepa, Shah, Neel, Day, Roger, Galluzzi, Lorenzo, Gardner, Mark, Morrison, Carl
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6346512/
https://ncbi.nlm.nih.gov/pubmed/30678715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0489-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi